Chen, H., Shen, C., Qie, Y., Lin, Y., Si, Q., Wu, Z., Yang, S., Jia, K., Xue, Z., Kang, N., Hu, H. (2026). Neoadjuvant tislelizumab in combination with disitamab vedotin (RC48) followed by distal ureterectomy for patients with HER-2 expressing lower segment ureteral carcinoma (LSUC): A single-arm, phase II, single-center study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.765